Association between several immune response‐related genes and the effectiveness of biological treatments in patients with moderate‐to‐severe psoriasis

• DOI: 10.1111/exd.15003
• Publication Date: 2024-01-05T06:43:44Z
• Authors: Alba Loras; Marta Gil‐Barrachina; Barbara Hernando; Gemma Perez‐Pastor; Alvaro Martinez‐D...; Laura Mahiques; Gerard Pitarch; Francisca Valcuen...; Rosa Ballester‐Sa...; Maria Angeles Mar...; Conrado Martinez‐...
• Keywords: psoriasis area severity index; PASI response; psoriasis; biological drugs; pharmacogenetics

Abstract Biological therapies are safer and more effective against psoriasis than conventional treatments. Even so, 30–50% of psoriatic patients show an inadequate response, which is associated with individual genetic heterogeneity. Pharmacogenetic studies have identified several single nucleotide polymorphisms (SNPs) as possible predictive prognostic biomarkers for treatment response. The objective this study was to determine the link between SNPs clinical response biological in moderate–severe psoriasis. A set 21 related and/or other immunological diseases were selected analysed from salivary samples ( n = 88). Treatment effectiveness patient improvement assessed clinically through Relative Psoriasis Area Severity Index (PASI), also called ‘PASI response’, well absolute PASI. Associations PASI factors at 3 12 months every category IL‐17, IL‐23, IL‐12&23 TNF‐α inhibitors. Multivariate correlation analysis Fisher's exact test used analyse relationship therapy outcomes. Several located TLR2 , TLR5 TIRAP HLA‐C IL12B SLC12A8 TNFAIP3 PGLYRP4 genes demonstrated association increased short long‐term therapy‐effectiveness rates. Most achieved values ≥75 or PASI<1, regardless administered. In conclusion, we demonstrate a different both short‐ especially terms These may be markers moderate‐to‐severe psoriasis, providing personalized treatment.